Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): Interim analysis of a phase II extension trial in relapsing-remitting multiple sclerosis

2017 ◽  
Author(s):  
Eva Havrdova
Keyword(s):  
Multiple Sclerosis ◽  
Phase Ii ◽  
Interim Analysis ◽  
Efficacy And Safety ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Extension Trial

scholarly journals Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

2014 ◽  
Vol 85 (11) ◽  
pp. 1198-1208 ◽  
Author(s):  
T. Olsson ◽  
A. Boster ◽  
O. Fernandez ◽  
M. S. Freedman ◽  
C. Pozzilli ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

CNS Drugs ◽  
2020 ◽  
Vol 34 (1) ◽  
pp. 65-92 ◽  
Author(s):  
Damiano Paolicelli ◽  
Alessia Manni ◽  
Antonio Iaffaldano ◽  
Maria Trojano
Keyword(s):  
Multiple Sclerosis ◽  
Efficacy And Safety ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document